Grifols (NASDAQ:GRFS) Reaches New 12-Month High - Here's Why

Grifols, S.A. (NASDAQ:GRFS - Get Free Report) shares hit a new 52-week high on Tuesday . The company traded as high as $10.00 and last traded at $9.77, with a volume of 863515 shares changing hands. The stock had previously closed at $9.72.

Analysts Set New Price Targets

A number of research analysts recently issued reports on GRFS shares. Wall Street Zen upgraded shares of Grifols from a "buy" rating to a "strong-buy" rating in a research report on Monday, July 7th. JPMorgan Chase & Co. boosted their target price on shares of Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a research report on Tuesday, June 17th.

Grifols Stock Up 3.3%

The company has a market capitalization of $6.94 billion, a price-to-earnings ratio of 8.62, a P/E/G ratio of 0.35 and a beta of 0.55. The business's 50-day moving average is $8.62 and its 200-day moving average is $7.80. The company has a quick ratio of 0.97, a current ratio of 2.60 and a debt-to-equity ratio of 1.13.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Versant Capital Management Inc acquired a new position in shares of Grifols in the first quarter worth about $28,000. Tower Research Capital LLC TRC raised its position in shares of Grifols by 354.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock worth $60,000 after acquiring an additional 6,335 shares during the period. First Trust Advisors LP acquired a new position in shares of Grifols in the fourth quarter worth about $75,000. Envestnet Portfolio Solutions Inc. acquired a new position in shares of Grifols in the fourth quarter worth about $77,000. Finally, Ballentine Partners LLC acquired a new position in shares of Grifols in the first quarter worth about $77,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.